Pins, Michael
Pins, Michael was paid $5.60M by Medicaid between Jan 2018 and Nov 2024, across 158 billing codes. Its largest line is 0241U, Neonatal screening for hereditary disorders, genomic sequence analysis panel — 14% of everything it billed.
33Billing provider infoPINS, MICHAEL
PARK RIDGE, IL 60068
PARK RIDGE, IL 60068
33aNPI1639155328assigned 12/15/2005
33bProvider typeSpecialist
28Total paid$5.60M
24GClaims898,518
24DCodes billed158
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Specialist providers in Illinois
Rank by total paid#2 of 273
Median peer was paid$32K
This provider vs. median174×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 121,032 | $618K | |
| 2019 | 143,505 | $734K | |
| 2020 | 13,768 | $93K | |
| 2021 | 117,137 | $771K | |
| 2022 | 176,356 | $1.46M | |
| 2023 | 168,813 | $1.06M | |
| 2024incomplete | 157,907 | $860K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 14% | 10,181 | 9,598 | $770K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 11% | 3,629 | 3,176 | $610K |
| 80053 | Comprehensive metabolic panel | 8.1% | 90,018 | 48,569 | $456K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 6.5% | 127,928 | 65,197 | $362K |
| 80048 | Basic metabolic panel (calcium, ionized) | 4.8% | 66,228 | 26,560 | $268K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 4.5% | 4,181 | 3,150 | $251K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 4.2% | 10,079 | 8,922 | $238K |
| 83735 | 3.6% | 59,593 | 18,536 | $201K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 2.6% | 6,783 | 6,565 | $147K |
| 87040 | 2.4% | 16,993 | 10,379 | $133K | |
| 87507 | 1.7% | 567 | 548 | $95K | |
| 84484 | 1.7% | 24,267 | 18,220 | $94K |
146 more codes
| 84100 | 1.6% | 44,025 | $92K | |
| 87641 | 1.5% | 3,735 | $83K | |
| 85027 | 1.4% | 28,043 | $80K | |
| 82803 | 1.3% | 9,823 | $74K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.3% | 14,849 | $74K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.2% | 1,828 | $70K |
| 83605 | 1.2% | 14,567 | $68K | |
| 84443 | Thyroid stimulating hormone (TSH) | 1.2% | 8,404 | $67K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 1.1% | 270 | $63K |
| 83880 | 1.1% | 5,702 | $63K | |
| 83690 | <1% | 16,541 | $55K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,049 | $47K |
| 86850 | <1% | 15,927 | $46K | |
| 80076 | <1% | 12,337 | $43K | |
| 85730 | <1% | 13,251 | $42K | |
| 86901 | <1% | 18,558 | $41K | |
| 88307 | <1% | 449 | $38K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,671 | $37K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,670 | $37K |
| 81001 | <1% | 25,718 | $36K | |
| 85610 | <1% | 18,409 | $35K | |
| 86140 | <1% | 14,572 | $34K | |
| 86900 | <1% | 18,555 | $31K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,054 | $30K |
| 84145 | <1% | 3,636 | $27K | |
| 82330 | <1% | 3,832 | $27K | |
| 84702 | <1% | 5,418 | $24K | |
| 87493 | <1% | 1,122 | $24K | |
| 85379 | <1% | 5,143 | $20K | |
| 82550 | <1% | 6,797 | $19K | |
| 82805 | <1% | 3,355 | $19K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 541 | $18K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 719 | $18K |
| 87186 | <1% | 2,582 | $17K | |
| 87075 | <1% | 2,698 | $17K | |
| 84703 | <1% | 4,832 | $17K | |
| 80202 | <1% | 2,527 | $16K | |
| 87070 | <1% | 5,290 | $16K | |
| 80061 | Lipid panel | <1% | 4,462 | $15K |
| 82607 | <1% | 2,540 | $15K | |
| 84439 | <1% | 3,185 | $14K | |
| 83615 | <1% | 4,881 | $13K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,220 | $13K |
| 82728 | <1% | 3,198 | $13K | |
| 87205 | <1% | 6,191 | $11K | |
| 85384 | <1% | 3,535 | $11K | |
| 82077 | <1% | 1,035 | $10K | |
| 82247 | <1% | 4,523 | $10K | |
| 0240U | <1% | 136 | $10K | |
| 82746 | <1% | 1,743 | $10K | |
| 87088 | <1% | 1,846 | $10K | |
| 83550 | <1% | 2,185 | $9K | |
| 80074 | <1% | 493 | $9K | |
| 85652 | <1% | 6,764 | $9K | |
| 85018 | <1% | 7,844 | $9K | |
| 85014 | <1% | 7,652 | $8K | |
| 82248 | <1% | 4,058 | $8K | |
| 89051 | <1% | 2,572 | $8K | |
| 81003 | <1% | 6,920 | $8K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 956 | $8K |
| 87340 | <1% | 1,146 | $7K | |
| 87077 | <1% | 2,106 | $7K | |
| 82570 | <1% | 2,973 | $7K | |
| 82140 | <1% | 1,598 | $7K | |
| 84132 | <1% | 3,535 | $7K | |
| 86665 | <1% | 559 | $7K | |
| 85046 | <1% | 2,224 | $6K | |
| 82150 | <1% | 1,760 | $6K | |
| 87015 | <1% | 1,550 | $6K | |
| 86706 | <1% | 843 | $6K | |
| 87081 | <1% | 1,885 | $5K | |
| 86803 | <1% | 636 | $5K | |
| 86704 | <1% | 651 | $5K | |
| 84550 | <1% | 2,365 | $5K | |
| 83655 | <1% | 767 | $5K | |
| 88304 | <1% | 251 | $4K | |
| 82962 | <1% | 4,814 | $4K | |
| 81025 | <1% | 2,301 | $4K | |
| 82747 | <1% | 568 | $4K | |
| 88342 | <1% | 172 | $4K | |
| 86880 | <1% | 1,203 | $3K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 139 | $3K |
| 84300 | <1% | 1,552 | $3K | |
| 86038 | <1% | 443 | $3K | |
| 86480 | <1% | 114 | $3K | |
| 86592 | <1% | 1,394 | $3K | |
| 84478 | <1% | 1,212 | $3K | |
| 84295 | <1% | 1,485 | $2K | |
| 84156 | <1% | 1,965 | $2K | |
| 87483 | <1% | 13 | $2K | |
| 83970 | <1% | 141 | $2K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 134 | $2K |
| 86645 | <1% | 201 | $2K | |
| 86870 | <1% | 246 | $2K | |
| 80164 | <1% | 415 | $2K | |
| 82565 | <1% | 878 | $2K | |
| 83935 | <1% | 675 | $2K | |
| 82977 | <1% | 793 | $2K | |
| 86769 | <1% | 51 | $2K | |
| 87806 | <1% | 155 | $2K | |
| 83930 | <1% | 612 | $1K | |
| 87449 | <1% | 186 | $1K | |
| 83516 | <1% | 204 | $1K | |
| 87206 | <1% | 551 | $1K | |
| 83540 | <1% | 397 | $1K | |
| 84481 | <1% | 237 | $1K | |
| 82010 | <1% | 470 | $1K | |
| 86077 | <1% | 41 | $1K | |
| 84157 | <1% | 908 | $1K | |
| 87102 | <1% | 317 | $979.90 | |
| 82945 | <1% | 644 | $977.69 | |
| 87116 | <1% | 157 | $927.00 | |
| 87045 | <1% | 144 | $880.08 | |
| 84134 | <1% | 272 | $733.31 | |
| 83010 | <1% | 149 | $644.03 | |
| 82784 | <1% | 102 | $634.46 | |
| 82533 | <1% | 82 | $556.93 | |
| 87807 | <1% | 118 | $526.82 | |
| 80143 | <1% | 46 | $525.46 | |
| 87497 | <1% | 20 | $456.20 | |
| 87427 | <1% | 73 | $436.14 | |
| 86644 | <1% | 69 | $433.55 | |
| 87899 | <1% | 75 | $400.14 | |
| 80050 | General health panel | <1% | 27 | $375.00 |
| 87046 | <1% | 190 | $357.84 | |
| 80179 | <1% | 32 | $357.76 | |
| 83993 | <1% | 39 | $264.43 | |
| 86920 | <1% | 92 | $250.61 | |
| 80177 | <1% | 53 | $237.24 | |
| 87653 | <1% | 13 | $228.15 | |
| 84520 | <1% | 100 | $160.35 | |
| 82274 | <1% | 25 | $131.84 | |
| 85520 | <1% | 29 | $113.97 | |
| 87147 | <1% | 69 | $109.86 | |
| 81002 | <1% | 87 | $109.00 | |
| 85461 | <1% | 38 | $103.98 | |
| 84450 | <1% | 46 | $94.47 | |
| 84146 | <1% | 12 | $80.52 | |
| 87210 | <1% | 29 | $68.15 | |
| 84460 | <1% | 31 | $61.67 | |
| 86060 | <1% | 13 | $55.90 | |
| 82042 | <1% | 17 | $43.13 | |
| 82272 | <1% | 13 | $17.55 | |
| 86923 | 0% | 76 | $0.00 | |
| 80329 | 0% | 592 | $0.00 | |
| 80320 | 0% | 2,223 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.